Highest development stage: Phase 4

Development active

Gram-positive activity

Mechanism of Action/Target pathogen: Approved for: acute bacterial skin and skin structure infections (ABSSSI); other potential indications: community-acquired bacterial pneumonia

Additional information: Dalbavancin: Phase I single and multiple-dose placebo controlled intravenous safety, pharmacokinetic study in healthy volunteers. 41st ICAAC
By: Leighton, A.; Mrosczcak, E.; White, R.; et al.